Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct;11(5):3299-3311.
doi: 10.1002/ehf2.14927. Epub 2024 Jul 1.

Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry

Affiliations
Observational Study

Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry

Takashi Kitao et al. ESC Heart Fail. 2024 Oct.

Abstract

Aims: Anaemia has been reported as poor predictor in heart failure with preserved ejection fraction (HFpEF). The aim of this study was to evaluate the impact of changes in haemoglobin (Hb) from discharge to 1 year after discharge on the prognosis using a lower cut-off value of Hb than the World Health Organization (WHO) criteria.

Methods and results: First, 547 HFpEF cases were divided into two groups, Hb < 11.0 g/dL (n = 218) and Hb ≥ 11.0 g/dL (n = 329), according to Hb at discharge, and further were divided according to Hb 1 year after discharge into Hb < 11.0 g/dL (G1, n = 113), Hb ≥ 11.0 g/dL (G2, n = 105), Hb < 11.0 g/dL (G3, n = 66), and Hb ≥ 11.0 g/dL (G4, n = 263), respectively. Major adverse cardiovascular events (MACE) was defined as composite of all-cause death and heart failure readmission after a visit 1 year after discharge. The cut-off value of Hb was analysed by the receiver operating characteristics curve that predicts MACE. We examined the incidence rate of MACE between G4 and other subgroups and verified predictors of improving or worsening anaemia and covarying factors with change in Hb. In multivariate Cox proportional hazard model, MACE was significantly higher in G3 with worsening anaemia from Hb ≥ 11.0 g/dL to <11.0 g/dL than G4 with persistently Hb ≥ 11 g/dL (adjusted hazard ratio (HR): 3.14 [95% confidence interval (CI), 1.76-5.60], P < 0.001). MACE was not significantly different between G2 with improving anaemia from Hb < 11.0 g/dL to ≥ 11.0 g/dL and G4 (adjusted HR: 1.37 [95% CI, 0.68-2.75], P = 0.38). In multivariate logistic regression analysis, independent predictors of improving anaemia were male [odds ratio (OR): 0.45], chronic obstructive pulmonary disease (OR: 10.3), prior heart failure hospitalization (OR: 0.38), and estimated glomerular filtration rate (OR: 1.04). Independent predictors of worsening anaemia were age (OR: 1.07), body mass index (BMI) (OR: 0.86), clinical frailty scale score (OR: 1.29), Hb at discharge (OR: 0.63), and use of angiotensin-converting-enzyme inhibitor or angiotensin II receptor blocker (OR: 2.76). In multivariate linear regression analysis, covarying factors with change in Hb were BMI (β = -0.098), serum albumin (β = 0.411), and total cholesterol (β = 0.179).

Conclusions: Change in haemoglobin after discharge using a lower cut-off value than WHO criteria has prognostic impact in patients with HFpEF.

Keywords: Acute decompensated heart failure; Change in haemoglobin; Heart failure with preserved ejection fraction; Worsening and improving anaemia.

PubMed Disclaimer

Conflict of interest statement

Shungo Hikoso has received remuneration from Daiichi Sankyo Company, Boehringer Ingelheim Japan, AstraZeneca K.K. and Bayer, and research funding from Roche Diagnostics, FUJIFILM Toyama Chemical and Bristol Myers Squibb. Hiroya Mizuno has received a department endowment from Terumo. Yohei Sotomi has received remuneration from Abbott Vascular Japan, Boston Scientific Japan, research funding from Abbott Vascular Japan, and a department endowment from Terumo. Yasushi Sakata has received remuneration from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo Company and AstraZeneca K.K., and research funding from Otsuka Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma, Kowa Company, Boehringer Ingelheim Japan, and Biotronik. Other authors (Akihiro Sunaga, Shunsuke Tamaki, Masahiro Seo, Masamichi Yano, Takaharu Hayashi, Akito Nakagawa, Yusuke Nakagawa, Hiroyuki Kurakami, Tomomi Yamada, Tetsuhisa Kitamura, Taiki Sato, Bolrathanak Oeun, Hirota Kida, Tomoharu Dohi, Katsuki Okada, Daisaku Nakatani, Takahisa Yamada, and Yoshio Yasumura) have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Flowchart of study patient subgrouping.
Figure 2
Figure 2
(A) Receiver operating characteristics curve analysis of haemoglobin predicting MACE for all patients. (B) Receiver operating characteristics curve analysis of haemoglobin predicting MACE for male. (C) Receiver operating characteristics curve analysis of haemoglobin predicting MACE for female.
Figure 3
Figure 3
Kaplan–Meier curves and log‐rank test from 1 year after discharge for subgroups.
Figure 4
Figure 4
Receiver operating characteristics curve analysis of eGFR in predicting improvement of anaemia.
Figure 5
Figure 5
Receiver operating characteristics curve analysis of age, BMI, Clinical Frailty Scale and haemoglobin predicting a worsening of anaemia.

Similar articles

Cited by

References

    1. Chinnaiyan KM, Alexander D, Maddens M, McCullough PA. Curriculum in cardiology: Integrated diagnosis and management of diastolic heart failure. Am Heart J 2007;153:189‐200. doi:10.1016/j.ahj.2006.10.022 - DOI - PubMed
    1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251‐259. doi:10.1056/NEJMoa052256 - DOI - PubMed
    1. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, et al. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014;35:2797‐2815. doi:10.1093/eurheartj/ehu204 - DOI - PMC - PubMed
    1. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12065 patients with new‐onset heart failure. Circulation 2003;107:223‐225. doi:10.1161/01.cir.0000052622.51963.fc - DOI - PubMed
    1. Hamaguchi S, Tsuchihashi‐Makaya M, Kinugawa S, Yokota T, Takeshita A, Yokoshiki H, et al. Anemia is an independent predictor of long‐term adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese cardiac registry of heart failure in cardiology (JCARE‐CARD). Circ J 2009;73:1901‐1908. doi:10.1253/circj.cj-09-0184 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources